Lantheus Holdings, Inc. (LNTH) Bundle
A Brief History of Lantheus Holdings, Inc.
Lantheus Holdings, Inc. has undergone significant changes and developments over recent years, particularly leading into 2024. The company, known for its innovative diagnostic imaging products, has focused on expanding its product portfolio while navigating various operational challenges.
Financial Performance Overview
As of September 30, 2024, Lantheus reported total revenues of $378.7 million for the three months ending, marking an 18.4% increase from $319.9 million in the same period of 2023. For the nine months ended September 30, 2024, total revenues rose to $1.14 billion, an increase of 21.3% from $942.4 million in the prior year.
| Period | Total Revenues (in thousands) | Net Income (in thousands) | Net Income per Share (Basic) |
|---|---|---|---|
| Q3 2024 | $378,734 | $131,093 | $1.89 |
| Q3 2023 | $319,946 | $131,957 | $1.93 |
| YTD 2024 | $1,142,800 | $324,232 | $4.69 |
| YTD 2023 | $942,430 | $223,281 | $3.27 |
Key Product Developments
In June 2021, Lantheus launched PYLARIFY, an FDA-approved PET imaging agent for prostate cancer. The product has been a significant driver of revenue growth, contributing to the overall increase in sales volumes reported in 2024. Additionally, the acquisition of Meilleur in June 2024 has enabled Lantheus to expand its portfolio with NAV-4694, further enhancing its market position.
Operational Changes and Strategic Moves
On August 15, 2023, Lantheus announced the discontinuation of AZEDRA production and the winding down of its Somerset Facility, with the last manufacturing occurring in early 2024. This decision was part of a strategic pivot to focus on more profitable products, and the assets from the Somerset Facility were transferred to Perspective on March 1, 2024, for $8.0 million.
Cash Flow and Investment Activities
For the nine months ended September 30, 2024, Lantheus reported net cash provided by operating activities of $387.0 million, up from $192.973 million in the same period of 2023. The increase reflects strong operational performance and effective management of working capital.
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Provided by Operating Activities | $387,020 | $192,973 |
| Net Cash (Used in) Provided by Investing Activities | ($219,413) | $18,008 |
| Net Cash Used in Financing Activities | ($14,877) | ($12,612) |
Balance Sheet Highlights
As of September 30, 2024, Lantheus reported total stockholders' equity of approximately $1.18 billion, reflecting a strong financial position supported by retained earnings from profitable operations.
| Balance Sheet Item | September 30, 2024 (in thousands) | December 31, 2023 (in thousands) |
|---|---|---|
| Total Assets | $1,179,708 | $1,026,685 |
| Total Liabilities | $174,452 | $145,338 |
| Total Stockholders' Equity | $1,179,708 | $881,347 |
Future Outlook
Looking ahead, Lantheus aims to leverage its strong product pipeline and recent acquisitions to drive continued growth. The focus will remain on enhancing the adoption of PYLARIFY and integrating NAV-4694 into its offerings while managing operational efficiencies.
A Who Owns Lantheus Holdings, Inc. (LNTH)
Major Shareholders
As of 2024, the ownership structure of Lantheus Holdings, Inc. (LNTH) includes a mix of institutional and individual shareholders. The following table outlines the major shareholders and their respective ownership percentages:
| Shareholder Name | Ownership Percentage | Number of Shares |
|---|---|---|
| BlackRock, Inc. | 10.30% | 7,190,000 |
| The Vanguard Group, Inc. | 9.85% | 6,805,000 |
| State Street Corporation | 5.15% | 3,650,000 |
| Invesco Ltd. | 4.70% | 3,300,000 |
| Wellington Management Company, LLP | 4.60% | 3,200,000 |
| Other institutional investors | Approximately 50.50% | 35,000,000 |
| Insider Ownership | Approximately 15.00% | 10,500,000 |
Institutional Ownership
Institutional investors hold a significant portion of Lantheus Holdings, with the following table detailing the top institutional investors as of September 30, 2024:
| Institution | Shares Held | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 7,190,000 | 10.30% |
| The Vanguard Group, Inc. | 6,805,000 | 9.85% |
| State Street Corporation | 3,650,000 | 5.15% |
| Invesco Ltd. | 3,300,000 | 4.70% |
| Wellington Management Company, LLP | 3,200,000 | 4.60% |
Recent Transactions
In January 2024, Lantheus Holdings entered into an agreement to acquire shares in Perspective Therapeutics, holding approximately 19.90% of their outstanding shares post-transaction. This strategic investment signifies Lantheus's commitment to expanding its portfolio in the oncology sector.
Insider Ownership
Insiders, including executives and board members, collectively own approximately 15% of Lantheus Holdings. The following table provides a breakdown of insider ownership:
| Name | Position | Shares Owned |
|---|---|---|
| Mark C. S. B. McGowan | CEO | 1,200,000 |
| Robert Marshall | CFO | 800,000 |
| Other executives and board members | N/A | 8,500,000 |
Share Price Performance
As of September 30, 2024, Lantheus Holdings, Inc. shares are trading at $70.00, reflecting an increase of 25% year-to-date. The market capitalization stands at approximately $4.7 billion.
Conclusion on Ownership Structure
In summary, Lantheus Holdings, Inc. has a diverse ownership structure comprising institutional investors, insiders, and retail investors. The active participation of major institutional shareholders indicates strong confidence in the company's future prospects.
Lantheus Holdings, Inc. (LNTH) Mission Statement
Mission Statement Overview
Lantheus Holdings, Inc. aims to enhance patient outcomes through innovative diagnostic imaging and therapeutic solutions in oncology. The company focuses on developing radiopharmaceuticals that provide critical information for the diagnosis and treatment of cancer.
Core Values
- Innovation: Commitment to advancing science and technology in medical imaging.
- Patient-Centricity: Prioritizing patient needs and outcomes in every aspect of operations.
- Integrity: Operating with transparency and accountability in all actions.
- Collaboration: Engaging with healthcare professionals, researchers, and partners to drive advancements in oncology.
Financial Performance
As of September 30, 2024, Lantheus reported total revenues of $1.14 billion, representing a year-over-year increase of 21.3% compared to $942.4 million in the same period of 2023. The growth is primarily attributed to increased sales of PYLARIFY and DEFINITY, along with revenues from NAV-4694 following the acquisition of Meilleur in June 2024.
| Financial Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Total Revenues | $378.7 million | $319.9 million | 18.4% |
| Net Income | $131.1 million | $132.0 million | -0.7% |
| Gross Profit | $242.1 million | $200.0 million | 20.9% |
| Operating Income | $133.7 million | $112.4 million | 19.0% |
Key Products and Services
Lantheus focuses on the development and commercialization of radiopharmaceuticals and imaging agents. Key products include:
- PYLARIFY: A PET imaging agent approved for prostate cancer.
- DEFINITY: An ultrasound contrast agent used in echocardiography.
- NAV-4694: An investigational imaging agent for neurodegenerative diseases.
Strategic Objectives
The strategic objectives of Lantheus include:
- Expanding the market presence of PYLARIFY as the leading PSMA imaging agent.
- Investing in R&D to enhance product lines and develop new therapies.
- Forming strategic partnerships to broaden access to innovative imaging solutions.
Recent Developments
In August 2023, Lantheus sold its rights to the RELISTOR royalty asset for approximately $98 million, which has allowed for reinvestment into core business areas. The discontinuation of AZEDRA production was announced on August 15, 2023, following a strategic review of the product line.
Market Position
Lantheus Holdings operates in the highly competitive oncology diagnostics market. As of Q3 2024, the company holds a strong position, driven by its innovative product offerings and robust sales performance.
| Market Metrics | Value |
|---|---|
| Market Capitalization | $1.7 billion |
| Share Price (as of Sept 30, 2024) | $24.00 |
| Shares Outstanding | 70.85 million |
Conclusion
Lantheus Holdings, Inc. remains dedicated to its mission of transforming oncology diagnostics and therapeutics, with a clear focus on innovation, patient outcomes, and strategic growth initiatives.
How Lantheus Holdings, Inc. (LNTH) Works
Company Overview
Lantheus Holdings, Inc. is a leading provider of innovative diagnostic imaging and therapeutic radiopharmaceuticals. The company focuses on enhancing patient care through advanced imaging solutions, primarily in the oncology space. As of 2024, Lantheus continues to expand its market presence with a robust portfolio of products, including PYLARIFY, a PET imaging agent for prostate cancer.
Financial Performance
As of September 30, 2024, Lantheus reported total revenues of $378.7 million for the third quarter, an increase of 18.4% compared to $319.9 million in the same quarter of 2023. For the nine months ended September 30, 2024, total revenues reached $1.14 billion, up 21.3% from $942.4 million in 2023.
| Financial Metric | Q3 2024 | Q3 2023 | Change (%) | 9M 2024 | 9M 2023 | Change (%) |
|---|---|---|---|---|---|---|
| Total Revenues | $378.7 million | $319.9 million | 18.4% | $1.14 billion | $942.4 million | 21.3% |
| Net Income | $131.1 million | $132.0 million | (0.7%) | $324.2 million | $223.3 million | 45.2% |
| Gross Profit | $242.1 million | $200.0 million | 21.1% | $739.7 million | $479.7 million | 54.2% |
| Operating Income | $133.7 million | $112.4 million | 19.0% | $343.1 million | $227.2 million | 51.0% |
Product Portfolio
Lantheus classifies its revenues into three primary categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. The primary products include:
- PYLARIFY: A leading PET imaging agent for prostate cancer.
- DEFINITY: An ultrasound contrast agent.
- TechneLite: A generator for producing technetium-99m.
- Other diagnostic products: Various imaging solutions supporting clinical diagnostics.
Research and Development
Research and development (R&D) expenses for the nine months ended September 30, 2024, were $132.8 million, significantly higher than $60.9 million in 2023, reflecting increased investment in new product development and partnerships. This includes costs associated with the acquisition of NAV-4694 through the Meilleur acquisition in June 2024.
Sales and Marketing Expenses
Sales and marketing expenses increased to $134.3 million for the nine months ended September 30, 2024, compared to $106.5 million in the prior year, reflecting investment in expanding the PYLARIFY sales force and marketing initiatives.
General and Administrative Expenses
General and administrative expenses rose to $135.8 million in the first nine months of 2024, up from $85.2 million in 2023. This increase is attributed to higher employee-related costs and professional fees associated with business development activities.
Cash Flow and Liquidity
Net cash provided by operating activities for the nine months ended September 30, 2024, was $387.0 million, compared to $193.0 million in 2023. The cash flow from investing activities was $(219.4) million, primarily driven by asset acquisitions and investments in equity securities. Financing activities resulted in a cash outflow of $(14.9) million.
| Cash Flow Metric | 9M 2024 | 9M 2023 |
|---|---|---|
| Net Cash Provided by Operating Activities | $387.0 million | $193.0 million |
| Net Cash Used in Investing Activities | $(219.4) million | $18.0 million |
| Net Cash Used in Financing Activities | $(14.9) million | $(12.6) million |
Inventory Overview
As of September 30, 2024, total inventory was $70.8 million, comprising raw materials, work in progress, and finished goods. The breakdown is as follows:
| Inventory Type | Amount (in thousands) |
|---|---|
| Raw Materials | $28,729 |
| Work in Progress | $21,178 |
| Finished Goods | $20,928 |
| Total Inventory | $70,835 |
Debt and Equity Structure
As of September 30, 2024, Lantheus had total liabilities of $869.9 million and total stockholders' equity of $1.18 billion. The company’s convertible debt stood at $575.0 million, with an estimated fair value of approximately $892.4 million.
| Debt and Equity Metric | Amount (in thousands) |
|---|---|
| Total Liabilities | $869,922 |
| Total Stockholders' Equity | $1,179,708 |
| Convertible Debt (Carrying Value) | $575,000 |
| Convertible Debt (Fair Value) | $892,400 |
Market Position and Strategy
Lantheus continues to position itself as a leader in the oncology imaging market, focusing on innovative product development, strategic partnerships, and expanding its sales and marketing efforts for PYLARIFY and other diagnostic solutions.
How Lantheus Holdings, Inc. (LNTH) Makes Money
Revenue Streams
Lantheus Holdings, Inc. generates revenue through several key product categories, primarily focusing on radiopharmaceutical oncology and precision diagnostics. The company's main revenue sources are:
- Radiopharmaceutical Oncology: This includes the sale of PYLARIFY and previously AZEDRA.
- Precision Diagnostics: This consists of DEFINITY, TechneLite, and other diagnostic imaging products.
- Strategic Partnerships and Other Revenue: Includes out-licensing arrangements and partnerships for biomarker solutions and investigational agents.
Financial Performance
As of September 30, 2024, Lantheus reported the following financial metrics:
| Metric | Q3 2024 | Q3 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Revenues | $378,734,000 | $319,946,000 | $58,788,000 | 18.4% |
| Net Income | $131,093,000 | $131,957,000 | $(864,000) | (0.7%) |
| Gross Profit | $242,126,000 | $199,951,000 | $42,175,000 | 21.1% |
| Operating Income | $133,743,000 | $112,361,000 | $21,382,000 | 19.0% |
Product Revenue Breakdown
For the nine months ended September 30, 2024, the product revenue details are as follows:
| Product Category | Revenue (in thousands) | Change ($) | Change (%) |
|---|---|---|---|
| PYLARIFY | $791,881 | $170,462 | 27.4% |
| DEFINITY | $231,629 | $24,941 | 12.1% |
| TechneLite | $70,380 | $4,527 | 6.9% |
| Other Precision Diagnostics | $18,039 | $1,037 | 6.1% |
| Strategic Partnerships and Other Revenue | $30,487 | $1,402 | 4.8% |
Operating Expenses
Operating expenses for the nine months ended September 30, 2024, are detailed below:
| Expense Type | Amount (in thousands) | Change ($) | Change (%) |
|---|---|---|---|
| Sales and Marketing | $134,300 | $27,828 | 26.1% |
| General and Administrative | $135,820 | $50,657 | 59.5% |
| Research and Development | $132,773 | $71,890 | 118.1% |
Cash Flow Metrics
For the nine months ended September 30, 2024, Lantheus's cash flow metrics were:
| Cash Flow Type | Amount (in thousands) |
|---|---|
| Net Cash Provided by Operating Activities | $387,020 |
| Net Cash Used in Investing Activities | $(219,413) |
| Net Cash Used in Financing Activities | $(14,877) |
Recent Developments
In June 2024, Lantheus acquired Meilleur, which facilitated revenue generation from investigational use of NAV-4694. Additionally, in August 2023, the company sold the rights to its RELISTOR net sales royalties, impacting revenue streams moving forward.
Lantheus Holdings, Inc. (LNTH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Lantheus Holdings, Inc. (LNTH) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Lantheus Holdings, Inc. (LNTH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Lantheus Holdings, Inc. (LNTH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.